Abstract:Background: The hallmarks of hepatic ischemia/reperfusion (I/R) injury, a common clinical problem that occurs during liver surgical procedures, include severe cell death and inflammatory responses that contribute to early graft failure and a higher incidence of organ rejection. Unfortunately, effective therapeutic strategies are limited. β-arrestins are multifunctional proteins that mediate receptor desensitization and serve as important signaling scaffolds in numerous physiopathological processes. However, the role of β-arrestins in hepatic I/R remains largely unknow. Methods: We overexpressed Arrb1 in the hepatocyte of C57BL/6 mice using an Arrb1 adeno-associated virus. Wide-type, Arrb1 overexpressing and knockout mice were subjected to a partial (70%) hepatic ischemia for 60 minutes, followed by various periods of reperfusion. Isolated hepatocytes from different group of mice were subjected to hypoxia-reoxygenation (H/R) injury to determine the in vitro effects of Arrb1. The molecular mechanisms underlying Arrb1-regulatd hepatic I/R injury were further explored and verified in mice. Findings: Here, we showed that only Arrb1 was downregulated during I/R-injured liver injury. Hepatocyte-specific overexpression of Arrb1 significantly ameliorated liver damage, as demonstrated by decreases in serum aminotransferases, hepatocellular necrosis and apoptosis, infiltrating inflammatory cells and secretion of pro-inflammatory cytokines relative to control mice. Whereas, experiments with Arrb1 knockout mice reveled opposite effects. Mechanistically, Arrb1 directly interacts with TRAF6 in hepatocyte, and inhibits the ubiquitination of TRAF6, which then prevents the activation of the downstream MAPK and NF-κB signaling pathways during hepatic I/R injury. Interpretation: The Arrb1-TRAF6 interaction inhibited the ubiquitination of TRAF6 and the activation of MAPK and NF-κB signaling, and then protected against cell death and inflammation, suggesting Arrb1 is a potential therapeutic target for hepatic I/R injury. Funding: This research was supported by grants from the 481 National Key Research and Development Program of China (2016YFC0905900), The State Key Program of National Natural Science Foundation of China (81430062), and the Innovative Research Groups of the National Natural Science Foundation (81521004 to B.S.). The authors declare no conflicts of interest. Declaration of Interest: The authors declare no potential conflicts of interest. Ethical Approval: Animal protocols were approved by the Animal Care and Use Committee of Nanjing Medical University, and experiments were conducted in adherence with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA). We gained permission from all the patients and healthy volunteers, and the procedures of our study on the basis of the basic principles of Helsinki Declaration were approved by the Ethics Committee of Nanjing Drum Tower Hospital.

Β-Arrestin 2 Promotes Hepatocyte Apoptosis by Inhibiting Akt Protein.

Arrb2 Causes Hepatic Lipid Metabolism Disorder Via AMPK Pathway Based on Metabolomics in Alcoholic Fatty Liver

Β-Arrestin-2 Attenuates Hepatic Ischemia-Reperfusion Injury by Activating PI3K/Akt Signaling

β-arrestin2 Inhibits Apoptosis and Inflammation of Liver Induced by Ischemia-reperfusion in Mice via AKT and TLR4 Pathway.

β-arrestin2 promotes angiogenesis of liver sinusoidal endothelial cells through the VEGF/VEGFR2 pathway to aggravate cirrhosis

Β-Arrestin 2 Mediates Cardiac Ischemia-Reperfusion Injury Via Inhibiting GPCR-independent Cell Survival Signalling.

β-Arrestin prevents cell apoptosis through pro-apoptotic ERK1/2 and p38 MAPKs and anti-apoptotic Akt pathways

Arrb1 Ameliorates Liver Ischemia/Reperfusion Injury Via Interacting with TRAF6 in Hepatocytes

Acetyl-Coenzyme A acyltransferase 2 attenuates the apoptotic effects of BNIP3 in two human cell lines.

Arrb2 Promotes Endothelial Progenitor Cell-Mediated Postischemic Neovascularization.

ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6-mediated Lysine 6-linked polyubiquitination of ASK1 in hepatocytes

β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling

Β-Arrestin 2 Negatively Regulates Toll-like Receptor 4 (Tlr4)-Triggered Inflammatory Signaling Via Targeting P38 MAPK and Interleukin 10.

β-arrestin 2 attenuates lipopolysaccharide-induced liver injury via inhibition of TLR4/NF-κB signaling pathway-mediated inflammation in mice.

β-Arrestin1 enhances liver fibrosis through autophagy-mediated Snail signaling.

β-arrestin-2 up-regulates toll-like receptor 2 signaling and inhibits apoptosis in human endometrial cancer heterotransplants in nude mice

β-Arrestin 2 regulates toll-like receptor 4-mediated apoptotic signalling through glycogen synthase kinase-3β: β-arrestin 2 regulates TLR4-mediated apoptosis

ARRB1 downregulates acetaminophen-induced hepatoxicity through binding to p-eIF2α to inhibit ER stress signaling

β-arrestin 2 regulates Toll-like receptor 4-mediated apoptotic signalling through glycogen synthase kinase-3β.

ARRB1 Protects Against Hepatic Ischemia-Reperfusion Injury Via Interaction with TRAF6

β‐arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-κB activation and autophagy induced by TLR3 and TLR4